Previous Infection and Effectiveness of COVID-19 Vaccination in Middle- and High-School Students

Details

• Alternative Title:
  Pediatrics
• Personal Author:
  Almendares, Olivia M. ; Ruffin, Jasmine D. ; Collingwood, Abigail H. ; Nolen, Leisha D. ; Lanier, William A. ; Dash, Sarah Rebecca ; Ciesla, Allison Avrich ; Wiegand, Ryan ; Tate, Jacqueline E. ; Kirking, Hannah L.
• Description:
  BACKGROUND AND OBJECTIVES:
  
  Understanding the real-world impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mitigation measures, particularly vaccination, in children and adolescents in congregate settings remains important. We evaluated protection against SARS-CoV-2 infection using school-based testing data.
  
  METHODS:
  
  Using data from Utah middle- and high-school students participating in school-wide antigen testing in January 2022 during omicron (BA.1) variant predominance, log binomial models were fit to estimate the protection of previous SARS-CoV-2 infection and coronavirus disease 2019 vaccination against SARS-CoV-2 infection.
  
  RESULTS:
  
  Among 17910 students, median age was 16 years (range: 12–19), 16.7% had documented previous SARS-CoV-2 infection; 55.6% received 2 vaccine doses with 211 median days since the second dose; and 8.6% of students aged 16 to 19 years received 3 vaccine doses with 21 median days since the third dose. Protection from previous infection alone was 35.9% (95% confidence interval [CI]: 12.9%–52.8%) and 23.8% (95% CI: 2.1%–40.7%) for students aged 12 to 15 and 16 to 19 years, respectively. Protection from 2-dose hybrid immunity (previous SARS-CoV-2 infection and vaccination) with <180 days since the second dose was 58.7% (95% CI: 33.2%–74.4%) for students aged 12 to 15 and 54.7% (95% CI: 31.0%–70.3%) for students aged 16 to 19 years. Protection was highest (70.0%, 95% CI: 42.3%–84.5%) among students with 3-dose hybrid immunity, although confidence intervals overlap with 2-dose vaccination.
  
  CONCLUSIONS:
  
  The estimated protection against infection was strongest for those with hybrid immunity from previous infection and recent vaccination with a third dose.
  
  
• Subjects:
  Adolescent Child COVID-19 COVID-19 Vaccines Humans SARS-CoV-2 Students Vaccination
• Source:
  Pediatrics. 152(6)
• Pubmed ID:
  37960897
• Pubmed Central ID:
  PMC11247457
• Document Type:
  Journal Article
• Funding:
  CC999999/ImCDC/Intramural CDC HHSUnited States/
• Volume:
  152
• Issue:
  6
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha-512:8fb84b86a4056546d92da4513e69a3545b57c882225dbc3e5e3d2ecceefcdc382bf107dbce3550a6531cc6a0717787f56a460759a51abd07c5ef9f7f838a2511
• Download URL:
  https://stacks.cdc.gov/view/cdc/159301/cdc_159301_DS1.pdf
• File Type:
  [PDF - 508.10 KB ]